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Background
Childhood maltreatment is one of the strongest predictors of
adulthood depression and alterations to circulating levels of
inflammatory markers is one putative mechanismmediating risk
or resilience.
Aims
To determine the effects of childhood maltreatment on circu-
lating levels of 41 inflammatory markers in healthy individuals
and those with a major depressive disorder (MDD) diagnosis.
Method
We investigated the association of childhood maltreatment with
levels of 41 inflammatory markers in two groups, 164 patients
with MDD and 301 controls, using multiplex electrochemilumi-
nescence methods applied to blood serum.
Results
Childhood maltreatment was not associated with altered
inflammatory markers in either group after multiple testing cor-
rection. Body mass index (BMI) exerted strong effects on inter-
leukin-6 and C-reactive protein levels in those with MDD.
Conclusions
Childhood maltreatment did not exert effects on inflammatory
marker levels in either the participants with MDD or the control
group in our study. Our results instead highlight the more per-
tinent influence of BMI.
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Worldwide, an estimated 25% of adults have reported physical
abuse in childhood. In the UK, the most comprehensive overview
of child protection states that there were 47 008 sexual offences
and 10 136 cruelty and neglect offences recorded against children
under the age of 16 in 2014/15.1 Childhood maltreatment has
been associated with a wide range of negative health consequences,
psychosocial outcomes and heightened risk for psychiatric
disorders; including anxiety disorder, bipolar disorder, delinquent
behaviour, impaired cognitive development and particularly
depression.2–4 Evidence suggests that numerous biological mechan-
isms become activated in response to maltreatment (for example
epigenetic changes, telomere erosion, cortisol dysregulation, inflam-
mation), which alone or in combination may explain the increased
vulnerability to disorders such as depression, among adults who
have been maltreated.5
Current understanding
Immunoinflammatory activation, and an increased release of proin-
flammatory cytokines, is one biological mechanism associated with
childhood maltreatment and an area of growing interest in psych-
iatry. Cytokines play an important role in brain development and
affect neurogenesis, synaptic remodelling and neurotransmitter
systems to produce behavioural change.6,7 Many studies have
reported an increase in proinflammatory cytokines such as interleu-
kin (IL)-1, IL-6 and tumour necrosis factor-alpha and increases in
the acute phase protein C-reactive protein (CRP) in patients with
major depressive disorder (MDD) and among those exposed tomal-
treatment.8 Whereas, others have reported protective effects of anti-
inflammatory cytokines such as IL-10.9
Aims
The current study investigated the association of inflammatory
marker levels in response to childhood maltreatment. Among
patients with MDD, we tested whether individuals who had been
maltreated had specific differences in levels of inflammatory
markers compared with those patients with MDD who had not
experienced maltreatment. The rationale for this was to determine
if individuals with MDD who had been maltreated represent
those with an inflammatory subtype of depression; which could
lead to differential diagnoses (for example depression with risk for
inflammatory disease) and subsequently novel intervention strat-
egies (such as anti-inflammatory adjuvants).
Among control participants, we tested whether individuals who
had been maltreated had altered inflammatory marker levels,
compared to those individuals who had not been maltreated. The
rationale for this was to identify whether alterations to specific
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components of the immune system might mark MDD resilience in
response to maltreatment, and therefore hint towards a novel treat-
ment strategy.
We addressed these aims by assessing 41 inflammatory
markers in a homogeneous treatment-resistant MDD cohort
recruited as part of the Antiglucocorticoid augmentation (metyra-
pone) of antiDepressants in Depression (ADD) study (n = 164),
and screened controls recruited as part of the South East London
Community Health Study (SELCoH, n = 301). In the case and
control groups separately, we investigated the association of inflam-
matory markers with the presence of childhood maltreatment.
Method
Participants
Peripheral blood samples used in this study were obtained by vene-
puncture as part of two separate UK studies. Controls were recruited
as part of SELCoH and participants with MDD were recruited as
part of the ADD study. Childhood maltreatment information was
collected within both studies. After collection, serum from both
studies were stored at−80°C until required. Participant information
relating to each study is detailed in Table 1 and a description of each
study is given below.
Control group
The participants in the control group were recruited as part of
SELCoH, which is a study in London, UK investigating mental
and physical health in the general South East London popula-
tion.10 Participants in this study received detailed and repeated
phenotypic assessments as part of three separate phases. The
first phase was carried out to assess common health disorders
and mental health disorders in South East London; the second
phase aimed to examine the roles of historical social context
and policy in shaping patterns of health inequalities; and in the
third phase, a number of biological specimens were collected
from a subset of participants including blood for serum separ-
ation. All phases collected information on psychiatric disorder
symptoms. Control participants were defined as those who
showed no MDD symptoms in any of the three phases of
SELCoH, determined using the Clinical Interview Schedule-
Revised,11 and who had no previous diagnosis of depression,
determined by a self-report questionnaire.
Case group
The participants with MDD (case group) were recruited as part of
the ADD study, which was a clinical trial that aimed to assess the
efficacy of metyrapone (a cortisol synthesis inhibitor) as an adjuvant
to selective serotonin reuptake inhibitors (SSRIs) in treating MDD
in those previously shown not to respond to at least two forms of
treatment (treatment-refractory MDD).12 Participants were
recruited from multiple UK centres, which included Manchester,
Leeds, Bradford and Newcastle.
Major depression diagnoses were defined using DSM-IV
criteria13 and assessed using the Structured Clinical Interview for
DSM Disorders research version.14 Further eligibility criteria
required participants to have a Hamilton Rating Scale for
Depression (HRSD) score greater than 18;15 have a Massachusetts
General Hospital Treatment Resistant Depression staging score of
2–10;16 be currently taking an SSRI; be aged between 18 and 65;
not have alcohol or drug dependence; be free of physical comorbid-
ities (untreated hypothyroidism, disorders of steroid production,
cardiac failure, angina, myocardial infarction, renal failure in the
past 3 years); and not take a medication that would contraindicate
metyrapone.We utilised blood serum collected during the screening
phase of the study.
Mild and major depression symptoms at the time of blood col-
lection, were differentiated using the HRSD, where HRSD scores of
18–19 were considered mild symptoms (no participants were
recruited with a HRSD <18), and HRSD scores of 20 and above were
considered moderate–severe symptoms, as described previously.15
Childhood maltreatment measure
The presence of childhood maltreatment was determined using the
Childhood Trauma Questionnaire (CTQ).17 CTQ data in our data-
sets were positively skewed and remained non-normal even after
log-transformation. Consequently, we generated ordinal mean
maltreatment measures,17 which, because of the small numbers of
individuals with severe maltreatment, we collapsed into ‘no maltreat-
ment’ (0) and ‘maltreatment’ (mild, moderate or severe maltreat-
ment) (1), (Table 1).
Ethics
For the ADD study, clinical trial authorisation was given by the
Medicines and Healthcare products Regulatory Agency (MHRA:
EudraCT: 2009-015165-31). Ethical approval was granted by the
Sunderland Local Research Ethics Committee (REC reference
number 10/H0904/9). The SELCoH study received approval from
the King’s College London research ethics committee, reference
PNM/12/13-152. Participants from both studies provided written
informed consent.
Inflammatory marker quantification
Upon use, serum was thawed at room temperature and 41 inflam-
matory markers were quantified simultaneously using multiplex
enzyme-linked immunosorbent assay-based technology provided
by the Meso Scale Discovery V-PLEX Plus Human Biomarker
40-Plex kit, and a customised human duplex kit assaying brain-
derived neurotrophic factor and interferon-alpha, as described pre-
viously.18 Seven-point standard curves were run in duplicate on
each plate in order to calculate absolute pg/mL values for the 80
samples assayed per plate, and a no-template control was used to
correct for background fluorescence. Case and control groups
were randomised across batches, and plates were scanned on the
Mesoscale Scale Discovery Meso Quickplex SQ 120 reader at the
Social, Genetic and Developmental Psychiatry Centre, Institute of
Psychiatry, Psychology and Neuroscience, King’s College London.
Table 1 Characteristics of the case and control groups
Characteristic
Case group, ADD
participants
Control group, SELCoH
participants
n 164 301
Age, years: mean (s.d.) 47.38 (9.63) 48.50 (16.14)
Gender, % men 40.9 47.5
Body mass index,
mean (s.d.)
31.54 (6.87) 26.93 (5.24)
Ethnicity, %
Black 1.8 20.9
White 94.5 75.4
Other 3.7 3.7
Current episode, n 164 0
On antidepressant, n 164 0
Current smoker, n 57 48
No maltreatment 56 256
Maltreatment 108 45
ADD, Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression
(ADD) study; SELCoH, South East London Community Health Study.
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Pilot studies revealed very high intraplate (r>0.99) and inter-
plate (r>0.97) correlations, suggesting single measurements were
acceptably reliable using this methodology. Furthermore, known
quantities within the standard curves used on each plate, correlated
very highly with quantities predicted by fluorescence intensity
(r>0.99).
Statistical analysis
Data processing
Standard curves were used to determine absolute quantities (pg/mL)
of each inflammatory marker. Absolute quantities (pg/mL)
were then log-transformed to allow for parametric analyses.
Subsequently, data points were removed if they exceeded plus or
minus 2 standard deviations from the mean. We excluded inflam-
matory markers where greater than 30% of data was missing.
Maltreatment analyses
For the case and control groups separately, we performed linear
regressions with log-protein level as the dependent variable and
childhood maltreatment as the independent variable, alongside eth-
nicity, smoking, antidepressant use, study site (ADD study), plate/
batch effects, gender, current depressive episode severity (ADD
study), age and BMI as covariates. Within our analyses we applied
the Bonferroni method of multiple testing correction, in order to
minimise risk for false associations.
Sensitivity analyses
We individually tested the potential mediating/confounding effects
of physical illness (type 2 diabetes, arthritis, cardiovascular disease,
stroke, high blood pressure and cancer) and socioeconomic status,
within the SELCoH study, where this data was available. Physical
illness information was obtained via self-report. Socioeconomic
status was determined based on an individual’s type of employment:
manual work, non-manual work, unemployed and economically
inactive (such as retired, full-time parents, students or those
unable to work because of disability). Based on our previous work
(which included SELCoH),18 we also attempted to replicate the
effects of BMI on levels of CRP and IL-6 (commonly shown to be
associated with maltreatment and MDD) in the ADD study, using
the same model as above.
Results
Inflammatory markers adequately detected in serum
Using our methodology, 34 inflammatory proteins passed our
quality control criteria. Seven inflammatory markers were found
to have greater than 30% missing data from across the whole
sample and were removed from any downstream analyses (macro-
phage inflammatory protein-1a, granulocyte-macrophage colony-
stimulating factor , IL-1a, IL-13, IL-1b, IL-2, IL-4). See Fig. 1 for a
summary of detectable inflammatory markers. Known quantities
within the standard curves used on all plates, correlated very
highly with quantities predicted by fluorescence intensity (r>0.99),
results also showed acceptably low levels of intraplate and interplate
variability based on coefficient of variation metrics. For further
details on correlations between different inflammatory markers,
and assay variability metrics, see supplementary Tables 1 and 2
available at https://doi.org/10.1192/bjo.2018.80.
Effect ofmaltreatment on inflammatorymarker levels in
case and control groups
We found no significant associations between childhood mal-
treatment and levels of inflammatory markers in controls
(Table 2). We found one nominally significant association
between maltreatment and levels of an inflammatory marker in
the MDD case group, whereby, childhood maltreatment was asso-
ciated with a reduction in circulating levels of serum amyloid A in
adulthood (F(1, 143) = 4.837, P = 0.029, variance explained,
3.3%). This effect did not remain significant following multiple
testing correction (Table 2).
Sensitivity analyses
We found no significant effects of physical illness, or socioeconomic
status on inflammatory markers (P>0.05). We replicated our previ-
ous work, showing strong positive correlations between BMI and
CRP levels (F(1, 86) = 29.489, P = 5.137 × 10–7, variance explained,
25.5%), and between BMI and IL-6 levels (F(1, 85) = 32.994,
P = 1.403 × 10–7, variance explained, 28%), in the ADD study.
Discussion
Main findings
Inflammation is one putative risk mechanism linking childhood
maltreatment to adulthood depression. This study sought to
investigate whether childhood maltreatment evokes differential
effects on inflammatory markers among participants with MDD
and controls. We studied the effects of maltreatment on 41
inflammatory markers in a UK sample of individuals with
MDD and screened controls while accounting for a broad range
of confounding factors.
We found no significant associations between childhood mal-
treatment and inflammatory markers in the control group, suggest-
ing that inflammation may not represent a mechanism conferring
resilience to MDD in response to maltreatment. Likewise, we did
not find a significant association between childhood maltreatment
and inflammatory markers among the case group, suggesting
there may not be an inflammatory subtype of MDD related to child-
hood maltreatment exposure.
Interpretation of our findings
Our negative results differ from the more common reports of higher
CRP and IL-6 levels in those with a history of childhood maltreat-
ment.3,19 A lack of replication here could relate to the fact that
not all studies have covaried for a broad range of confounding
factors as we do. For instance, studies have revealed that childhood
maltreatment is associated with higher adulthood BMI, and conse-
quently this could partially mediate previously reported associa-
tions.20–22 Indeed, we have recently reported major influences of
BMI (as well as other factors) on inflammatory marker levels,
namely CRP and IL-6, which once covaried for, removes MDD
case–control differences in inflammatory marker levels.18 Here,
we replicate the effects of BMI on CRP and IL-6 levels in the
ADD study, confirming the necessity to appropriately covary for
BMI and other confounders in statistical models relating to inflam-
matory measures.
The effect of BMI on inflammatory levels likely results from the
fact that adipose tissue is known to release adipokines and proin-
flammatory cytokines.23–25 Therefore, regardless of what causes
heightened inflammation among the participants with MDD or
individuals who were maltreated, weight management via balanced
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Fig. 1 Detectable inflammatory markers.
(a) Lowly expressed protein, < 1 pg/mL; (b) low–moderately expressed protein, 1 – 20 pg/mL; (c) moderate–highly expressed protein, 21 –
400 pg/mL; (d) highly expressed protein, 401 – 25,000 pg/mL; (e) very highly expressed protein, 25,001 – 100,000,000 pg/mL. Bars represent the
mean and error bars represent the standard error of themean. TNF, tumour necrosis factor; IL, interleukin; IFN, interferon; bFGF, basic fibroblast
growth factor; PIGF, phosphatidylinositol glycan biosynthesis class F protein; MCP, monocyte chemoattractant protein 4; sFLT, soluble fms-like
tyrosine kinase; MIP, macrophage inflammatory protein; IP, induced protein; TARC, chemokine (C-C motif) ligand 17 (also known as CCL17);
VEGF, vascular endothelial growth factor; MDC, macrophage-derived chemokine; Tie, tyrosine kinases with immunoglobulin-like and EGF-like
domains; BDNF, brain-derived neurotrophic factor; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion
molecule; CRP, C-reactive protein; SAA, serum amyloid A.
Palmos et al
4
diets and regular exercise, may be one method to reduce excessive
inflammation.
Strengths and limitations
The strengths of the current study include the fact we assessed a
broad range of inflammatory proteins using validated electrochemi-
luminescence methods; we used a well-characterised method of
assessment for childhood maltreatment subtypes; we statistically
corrected for a number of confounding factors and performed
appropriate sensitivity analyses; and we performed analyses in a
screened control group and a homogeneous treatment-resistant
MDD cohort.
However, the study also has a number of limitations that should
be acknowledged. First, and foremost, our study is of a cross-sec-
tional design capturing inflammation levels only in adulthood.
A longitudinal design would allow one to determine the temporal
ordering of events, and measure how maltreatment has an impact
on inflammation immediately, during adolescence and then in
adulthood; identifying acute and persistent effects, if any, on inflam-
matory markers. Second, maltreatment was captured as a binary
variable and we were underpowered to assess the effects of maltreat-
ment severity. As the majority of a individuals who had been
maltreated in our two samples experienced mild–moderate mal-
treatment as opposed to severe maltreatment, it is possible that
the biological embedding effects of stress are less penetrant in our
sample, which is why we did not observe broad effects on inflamma-
tory marker levels.
Third, all the participants with MDD were currently on anti-
depressant treatment, as per the recruitment criteria. As antidepres-
sants are known to possess some anti-inflammatory properties, it is
possible this may be masking the long-term effects of maltreatment
on immunoinflammatory function.26 Fourth, the CTQ measure of
childhood maltreatment is widely used and although reliable, argu-
ably lacks validity and is subject to the biases of retrospective recall,
especially in individuals with high neuroticism.27 Despite this, it is
important to note that recent research shows a moderate–strong
positive correlation between CTQ and prospective measures of mal-
treatment, collected as part of longitudinal studies, validating the
usefulness of the CTQ as a tool for assessing maltreatment severity.28
Fifth, there may be other confounding factors influencing
inflammatory marker levels that we were not able to include here
(such as time and season of blood collection) that may have affected
our results. Finally, despite representing one of the larger single
studies to date assessing disorder-specific effects of maltreatment,
we may still be underpowered; therefore, future studies with even
larger sample sizes may be able to confirm our largely negative
findings.
In conclusion, our study does not support previous research
revealing associations between childhood maltreatment and inflam-
matory markers in either participants with MDD or controls.
Instead, our findings suggest that other factors such as BMI may
be more pertinent in influencing inflammatory marker levels.
Table 2 Analysis of associations between childhood maltreatment and levels of inflammatory markers in the case and control groups
Marker name and abbreviation
Control group Case group
F d.f. P
Variance
explained, % F d.f. P
Variance
explained, %
Phosphatidylinositol glycan biosynthesis class F protein (PIGF) 2.564 279 0.110 0.9 0.032 145 0.859 0.0
Tyrosine kinases with immunoglobulin-like and EGF-like domains (Tie)-2 2.705 281 0.101 1.0 1.399 147 0.239 0.9
Vascular endothelial growth factor (VEGF) 2.049 277 0.153 0.7 1.212 133 0.273 0.9
VEGF-C 0.056 283 0.813 0.0 0.001 133 0.979 0.0
VEGF-D 2.523 280 0.113 0.9 0.875 128 0.351 0.7
Basic fibroblast growth factor (bFGF) 0.003 281 0.955 0.0 0.144 122 0.705 0.1
Soluble fms-like tyrosine kinase (sFlt-1) 0.072 280 0.788 0.0 0.255 146 0.614 0.2
Eotaxin 0.594 275 0.442 0.2 0.014 142 0.906 0.0
Eotaxin-3 2.016 245 0.157 0.8 0.035 120 0.851 0.0
Induced protein (IP)-10 0.481 277 0.488 0.2 1.226 133 0.270 0.9
Monocyte chemoattractant protein (MCP)-1 2.830 283 0.094 1.0 0.022 143 0.882 0.0
MCP-4 0.955 275 0.329 0.3 0.509 137 0.477 0.4
Macrophage-derived chemokine (MDC) 0.365 276 0.546 0.1 0.024 134 0.876 0.0
Macrophage inflammatory protein (MIP)-1b 0.200 279 0.655 0.1 0.463 134 0.497 0.3
Chemokine (C-C motif) ligand 17 (TARC)a 0.174 282 0.677 0.1 0.812 137 0.369 0.6
Brain-derived neurotrophic factor (BDNF) 0.536 268 0.465 0.2 0.983 130 0.323 0.8
Interferon (IFN)-alpha 2.870 215 0.092 1.3 0.000 97 0.985 0.0
Interleukin (IL)-12 0.012 283 0.912 0.0 0.532 144 0.467 0.4
IL-15 0.763 281 0.383 0.3 0.137 145 0.712 0.1
IL-16 2.106 284 0.148 0.7 3.051 133 0.083 2.2
IL-17 2.039 265 0.154 0.8 0.031 140 0.861 0.0
IL-5 3.007 196 0.084 1.5 2.750 131 0.100 2.1
IL-7 1.015 284 0.314 0.4 0.141 136 0.708 0.1
Tumour necrosis factor (TNF)-beta 0.344 268 0.558 0.1 1.717 129 0.192 1.3
IFN-gamma 0.033 270 0.855 0.0 0.492 140 0.484 0.4
IL-10 0.103 265 0.749 0.0 0.230 133 0.632 0.2
IL-12p70 0.096 251 0.757 0.0 2.286 114 0.133 2.0
IL-6 0.030 265 0.864 0.0 1.693 138 0.195 1.2
IL-8 2.969 286 0.086 1.0 2.222 130 0.139 1.7
TNF 0.464 282 0.496 0.2 0.073 139 0.787 0.1
C-reactive protein (CRP) 0.002 272 0.960 0.0 3.770 141 0.054 2.6
Serum amyloid A (SAA) 1.301 266 0.255 0.5 4.837 143 0.029 3.3
Soluble intercellular adhesion molecule (slCAM)-1 1.717 272 0.191 0.6 1.363 147 0.245 0.9
Soluble vascular cell adhesion molecule (sVCAM)-1 0.530 269 0.467 0.2 0.858 148 0.356 0.6
a. Also known as CCL17.
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